Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model

http://www.wlf.org/upload/03-21-08balukina.pdf

ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model

PRINCETON, N.J., March 21 /PRNewswire-USNewswire/ -- In a short article published today by the Washington Legal Foundation, US international trade and business lawyer Lawrence Kogan and Russian Government lawyer Yelena Bakulina highlight the common bases in Russian and US history that have triggered new thinking in Russia about how to use privately owned patent rights and cooperative government-university-industry technology transfer arrangements to secure successful market commercialization and peaceful adaptation of publicly-owned bio-warfare technologies.

The article arose from Kogan's June 28, 2007 presentation at a symposium convened by the Vyatka State University, Kirov, Russia, [http://www.vshu.kirov.ru/] as part of a longstanding joint Russian-US cooperative nonproliferation program overseen by the International Science and Technology Center (ISTC), Moscow, Russia. [http://www.istc.ru/]

According to Bakulina and Kogan, "The [US] federal government['s]...transference of innovation from energy, space, and defense to that of the private sector, and...the American experience in innovation and intellectual property may be advantageous to use in Russia..."

Furthermore as the authors note, "The Kirov Region certainly has the potential to develop effective innovation systems supported by the investment and protection of privately owned intellectual property in the sphere of modern high tech technology. If properly managed...this could create jobs, know-how and other economic and social benefits in the Kirov Region."


"Such an approach," adds Kogan, "would allow Russian biotechnology markets to leapfrog those of the European Union to capture a greater share of the global marketplace for biomedical and bioenvironmental products and processes. Unfortunately, the current EU innovation model is fixated on governmental market control via regulation rather than on market facilitation via economic incentives that ease the burdens and costs of doing business," emphasizes Kogan. "The EU Commission is more obsessed with dictating the rules of the game to ensure 'parity-over-progress' than with providing hi tech European businesses operating in the biotech sectors with
the necessary property rights-based enabling environment and economic freedom to grow and prosper. "Consequently," Kogan notes, "EU biotech and pharma companies have increasingly relocated operations to the US."


The Institute for Trade, Standards and Sustainable Development (ITSSD) is a non-partisan non-profit international legal research and educational organization that examines international law relating to trade, industry and positive sustainable development around the world. This and related ITSSD articles are accessible online at:
http://www.itssd.org/Publications/03-21-08balukina.pdf; http://www.itssd.org/ and http://itssdinternationaliprights.blogspot.com/.


CONTACT: ITSSD, +1-609-951-2222, info@itssd.org

Bush Administration Sees Wisdom of Preserving US Global Competitiveness in Life Sciences; IT Coalition Patent Reform Position Deemed Spurious

http://sfgate.com/cgi-bin/article.cgi?f=/c/a/2008/02/05/BUOGURRUS.DTL


Bush staff, tech titans split over patent bill


Tom Abate, Chronicle Staff Writer


Tuesday, February 5, 2008


The Bush administration said Monday that it opposes a key provision of a patent reform bill that has passed the House of Representatives and is awaiting a floor vote in the Senate, taking sides in an intellectual war over how best to promote innovation.


The position puts the administration at odds with big technology firms like Intel, IBM, Apple, Google, Cisco and Hewlett-Packard that have banded together to push the bill, and squarely on the side of the biotech and venture capital industries, which say the proposed change would significantly weaken patents.


A patent is a government-issued monopoly that gives inventors the legal right to control the use of their discoveries for up to 20 years.


[A PATENT IS RECOGNIZED AS A PROPERTY RIGHT OF TEMPORARY DURATION UNDER U.S. CONSTITUTIONAL AND CIVIL LAW]


In a six-page letter written on behalf of the U.S. Patent and Trademark Office, the administration told senators that it disagrees with a provision that would change the way damages are calculated in cases when patent infringement is proven. That change "could promote infringement,"the administration warned, saying it would oppose the legislation unless the bill is changed to "protect the inventor."


"What the administration is saying on damages is our position as well," said Kelly Slone with the National Venture Capital Association, which has sent senators a letter signed by Kleiner Perkins Caufield and Byers, New Enterprise Associates and others.


Mark Isakowitz, a lobbyist with the tech-sponsored Coalition for Patent Fairness, downplayed the significance of Monday's letter, saying the administration made much the same argument before the House passed its patent bill by a 220-175 vote in autumn.


"We strongly and respectfully disagree with their view," said Isakowitz, adding that he still expects the bill to come up for a floor vote in the Senate around the end of February. "Between now and then we have to try and reach a broader consensus on damages," he said.


Patents are authorized in Article I of the Constitution, which gives Congress the power "To promote the Progress of Science." But the Constitution does not say exactly how, which has meant a never-ending series of arguments, said Kenneth Dobyns, a retired patent attorney who wrote a history of the system called "The Patent Office Pony."


"There's never been a time when it wasn't like this," Dobyns said.


At the heart of the current dispute is the fact that patents, which have been on a sort of pendulum swing throughout U.S. history, from worth very little to worth very much, are somewhere at the high end of their historical value.


The reasons have little to do with Congress, which has not really changed patent law since 1952, but rather with a reorganization of the federal court system in the 1980s. That change created what amounts to a special court of appeals for patent cases that has, generally speaking, ended up strengthening patent law, according to Bronwyn Hall, a UC Berkeley economist who has studied the situation.


Perhaps the high point of patent strength, at least to members of Congress, came in recent years when the Canadian company Research In Motion paid $612.5 million in March to settle a patent dispute that had very nearly lead to a court-ordered injunction stopping sales of the BlackBerry device, which is popular on Capitol Hill.


The size of the settlement and the drama leading up to it lent credence to tech industry complaints about patents.


"We have a system which is out of whack, out of balance," said Tim Sheehy, a Capitol Hill lobbyist for IBM Corp., which backs the current language on damages that the White House opposes.


Biotech industry leaders feel particularly threatened by proposed changes because their whole industry has grown up in the past 25 years when, largely thanks to court actions, patents have become more and more valuable.


"If it comes down to a choice between a tilt toward the iPod or a tilt toward cancer cures, I think that's a no-brainer," said James Greenwood, president of Biotechnology Industry Organization.


What remains to be seen is whether the disagreement over damages can be ironed out, or whether the bill will stall.


"A forced choice is a false choice. The current proposal forces a choice of promoting one innovation over another," said Patent Office Director Jon Dudas, who held out hope of an agreement being reached.


E-mail Tom Abate at tabate@sfchronicle.com.
http://sfgate.com/cgi-bin/article.cgi?f=/c/a/2008/02/05/BUOGURRUS.DTL